Avillion Inks Drug Development Deal with Pearl Therapeutics

Avillion, a drug development company, has signed a clinical codevelopment agreement with Pearl Therapeutics Inc., a wholly owned subsidiary of the AstraZeneca Plc group, to advance PT027 through a global clinical development programme for the treatment of asthma.

PT027 is an investigational fixed dose combination of budesonide (an inhaled corticosteroid) and albuterol (a shortacting beta-2 agonist). Avillion will be responsible for developing PT027 through an extensive clinical development programme and will finance the programme through to regulatory approval. No financial terms are disclosed.

Avillion is a drug development company with an innovative business model focusing on the clinical co-development and regulatory approval of pharmaceutical products.